View More View Less
  • 1 Kaposi Mór Megyei Kórház, Szemészeti Osztály, Kaposvár
  • 2 Pécsi Tudományegyetem, Gyógyszerésztudományi Kar, Gyógyszertechnológiai és Biofarmáciai Intézet, Pécs
  • 3 Pécsi Tudományegyetem, Gyógyszerésztudományi Kar, Farmakognóziai Intézet, Pécs
  • 4 Semmelweis Egyetem, Általános Orvostudományi Kar, Szemészeti Klinika, Budapest, Üllői út 26., 1085
  • 5 Semmelweis Egyetem, Egészségtudományi Kar, Budapest

Összefoglaló. A szárazszem-panaszok hátterében gyakran áll Meibom-mirigy-diszfunkció, melynek felismerése kiemelten fontos a hatékony kezelés érdekében. A Meibom-mirigyek kóros működése miatt a termelt lipid nem oszlik el megfelelően a szemfelszínen, így a könnyfilm párolgása fokozódik. A könnytermelési zavar következtében szárazszem-panaszok alakulnak ki, melyek a hagyományos könnypótló kezelésre rendszerint csak átmenetileg javulnak. A Meibom-mirigy-diszfunkciót gyakran kíséri a szemhéjszél Demodex-atka-fertőzése – az atka eradikálása szükséges a mirigyek működésének helyreállításához és ezáltal a panaszok megszüntetéséhez. A Meibom-mirigy-diszfunkció a leggyakrabban enyhe formában jelentkezik; a terápia ilyenkor a beteg által is elvégezhető szemhéjtisztításból áll, míg a gyógyszeres kezelés csak az előrehaladottabb, kifejezett gyulladással járó formákban szükséges. Az összefoglaló áttekinti a Meibom-mirigy-diszfunkció klinikai jeleivel és kezelésével kapcsolatos legfontosabb tudnivalókat, különös tekintettel a Demodex-fertőzés felismerésére és kezelésére vonatkozóan. Orv Hetil. 2021; 162(2): 43–51.

Summary. The onset of dry eye complaints is often a result of Meibomian gland dysfunction and its diagnosis is essential for effective treatment. In the case of Meibomian gland dysfunction, there is an increased evaporation of the tear film due to the abnormal secretion of lipids that cannot spread on the ocular surface. The treatment of dry eye complaints associated with Meibomian gland dysfunction with tear supplementation is usually ineffective and only results in an intermittent relief of complaints. Meibomian gland dysfunction is often associated with Demodex infestation of the eyelids, and eradicating the mites is essential to re-establish normal meibum production and thus, decreasing ocular complaints. In most cases, Meibomian gland dysfunction is mild, and the treatment of these forms is based on ocular hygiene performed by the patient, while only more advanced forms with inflammatory processes require pharmacologic treatment. This review summarizes the most important knowledge on the clinical signs and treatment of Meibomian gland dysfunction with particular attention to the diagnosis and treatment of ocular Demodex infection. Orv Hetil. 2021; 162(2): 43–51.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Knop E, Knop N, Millar T, et al. The International Workshop on Meibomian Gland Dysfunction: report of the Subcommittee on Anatomy, Physiology, and Pathophysiology of the Meibomian Gland. Invest Ophthalmol Vis Sci. 2011; 52: 1938–1978.

  • 2

    Berta A, Tóth-Molnár E, Csutak A. New international consensus statement about the definition, classification, ethiology, diagnostics and therapy of dry eye (TFOS DEWS II). [Új nemzetközi konszenzusnyilatkozat a száraz szem definíciójáról, felosztásáról, etiológiájáról, diagnosztikájáról és terápiájáról.] Orv Hetil. 2018; 159: 775–785. [Hungarian]

  • 3

    Schaumberg DA, Nichols JJ, Papas EB, et al. The International Workshop on Meibomian Gland Dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011; 52: 1994–2005.

  • 4

    Borchman D, Foulks GN, Yappert MC, et al. Human meibum lipid conformation and thermodynamic changes with meibomian-gland dysfunction. Invest Ophthalmol Vis Sci. 2011; 52: 3805–3817.

  • 5

    Shimazaki J, Sakata M, Tsubota K. Ocular surface changes and discomfort in patients with meibomian gland dysfunction. Arch Ophthalmol. 1995; 113: 1266–1270.

  • 6

    Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. Br J Ophthalmol. 1984; 68: 524–528.

  • 7

    Liu J, Sheha H, Tseng SC. Pathogenic role of Demodex mites in blepharitis. Curr Opin Allergy Clin Immunol. 2010; 10: 505–510.

  • 8

    Lee SH, Chun YS, Kim JH, et al. The relationship between Demodex and ocular discomfort. Invest Ophthalmol Vis Sci. 2010; 51: 2906–2911.

  • 9

    Kim JH, Chun YS, Kim JC. Clinical and immunological responses in ocular demodecosis. J Korean Med Sci. 2011; 26: 1231–1237.

  • 10

    Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5: 163–178.

  • 11

    Post CF, Juhlin E. Demodex folliculorum and blepharitis. Arch Dermatol. 1963; 88: 298–302.

  • 12

    Jalbert I, Rejab S. Increased numbers of Demodex in contact lens wearers. Optom Vis Sci. 2015; 92: 671–678.

  • 13

    Preisz K, Kárpáti S. Rosacea: pathogenesis, clinical forms and therapy. [A rosacea patogenezise, klinikai formái és kezelése.] Orv Hetil. 2010; 151: 1209–1214. [Hungarian]

  • 14

    Geerling G, Tauber J, Baudouin C, et al. The International Workshop on Meibomian Gland Dysfunction: report of the Subcommittee on Management and Treatment of Meibomian Gland Dysfunction. Invest Ophthalmol Vis Sci. 2011; 52: 2050–2064.

  • 15

    Dougherty JM, McCulley JP. Bacterial lipases and chronic blepharitis. Invest Ophthalmol Vis Sci. 1986; 27: 486–491.

  • 16

    Mastrota KM. Method to identify Demodex in the eyelash follicle without epilation. Optom Vis Sci. 2013; 90: e172–e174.

  • 17

    Coston TO. Demodex folliculorum blepharitis. Trans Am Ophthalmol Soc. 1967; 65: 361–392.

  • 18

    Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop. Ocul Surf. 2007; 5: 108–152.

  • 19

    Tóth-Molnár E. Treatment of dry eye disease. Present and future. [A száraz szem kezelésének stratégiája: jelenlegi ajánlások, jövőbeni lehetőségek.] Szemészet 2020; 157: 1–10. [Hungarian]

  • 20

    Módis L. Therapy of the dry eye disease. In: Süveges I. (ed.) Ocular surface and cornea diseases. [A száraz szem terápiája. In: Süveges I. (szerk.) A szemfelszín és cornea betegségei.] Medicina Könyvkiadó, Budapest, 2020; pp. 45–63. [Hungarian]

  • 21

    Key JE. A comparative study of eyelid cleaning regimens in chronic blepharitis. CLAO J. 1996; 22: 209–212.

  • 22

    Guillon M, Maissa C, Wong S. Eyelid margin modification associated with eyelid hygiene in anterior blepharitis and meibomian gland dysfunction. Eye Contact Lens 2012; 38: 319–325.

  • 23

    Korb DR, Blackie CA, Finnemore VM, et al. Effect of using a combination of lid wipes, eye drops, and omega-3 supplements on meibomian gland functionality in patients with lipid deficient/evaporative dry eye. Cornea 2015; 34: 407–412.

  • 24

    Jackson WB. Blepharitis: current strategies for diagnosis and management. Can J Ophthalmol. 2008; 43: 170–179.

  • 25

    Wong K, Flanagan J, Jalbert I, et al. The effect of BlephadexTM eyelid wipes on Demodex mites, ocular microbiota, bacterial lipase and comfort: a pilot study. Cont Lens Anterior Eye 2019; 42: 652–657.

  • 26

    Greiner JV, Leahy CD, Glonek T, et al. Effects of eyelid scrubbing on the lid margin. CLAO J. 1999; 25: 109–113.

  • 27

    Hueso Abancens JR, Mengual Verdú E, Schargel Palacios K, et al. Modification of the conjuntival flora with cleaning palpebral solutions. [Modificación de la flora conjuntival por el empleo de soluciones de higiene palpebral.] Arch Soc Esp Oftalmol. 2004; 79: 617–621. [Spanish]

  • 28

    Peral A, Alonso J, García-García C, et al. Importance of lid hygiene before ocular surgery: qualitative and quantitative analysis of eyelid and conjunctiva microbiota. Eye Contact Lens 2016; 42: 366–370.

  • 29

    Ávila MY, Martínez-Pulgarín DF, Rizo Madrid C. Topical ivermectin-metronidazole gel therapy in the treatment of blepharitis caused by Demodex spp.: a randomized clinical trial. Cont Lens Anterior Eye 2020 May 24. . [Online ahead of print]

    • Crossref
    • Export Citation
  • 30

    Fulk GW, Murphy B, Robins MD. Pilocarpine gel for the treatment of demodicosis – a case series. Optom Vis Sci. 1996; 73: 742–745.

  • 31

    Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017; 15: 575–628.

  • 32

    Hammer K, Carson, Riley CT. Antifungal activity of the components of Melaleuca alternifolia (tea tree) oil. J Appl Microbiol. 2003; 95: 853–860.

  • 33

    Gao YY, DiPascuale MA, Li W, et al. In vitro and in vivo killing of ocular Demodex by tea tree oil. Br J Ophthalmol. 2005; 89: 1468–1473.

  • 34

    Gao YY, Xu D, Huang lJ, et al. Treatment of ocular itching associated with ocular demodicosis by 5% tea tree oil ointment. Cornea 2012; 31: 14–17.

  • 35

    Kabat AG. In vitro demodicidal activity of commercial lid hygiene products. Clin Ophthalmol. 2019; 13: 1493–1497.

  • 36

    Gao YY, Di Pascuale MA, Elizondo A, et al. Clinical treatment of ocular demodecosis by lid scrub with tea tree oil. Cornea 2007; 26: 136–143.

  • 37

    Ngo W, Jones L, Bitton E. Short-term comfort responses associated with the use of eyelid cleansing products to manage Demodex folliculorum. Eye Contact Lens 2018; 44(Suppl 2): S87–S92.

  • 38

    Arita R, Morishige N, Shirakawa R, et al. Effects of eyelid warming devices on tear film parameters in normal subjects and patients with meibomian gland dysfunction. Ocul Surf. 2015; 13: 321–330.

  • 39

    Greiner JV. Long-term (12-month) improvement in meibomian gland function and reduced dry eye symptoms with a single thermal pulsation treatment. Clin Exp Ophthalmol. 2013; 41: 524–530.

  • 40

    Arita R, Fukuoka S, Morishige N. Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocul Surf. 2019; 17: 104–110.

  • 41

    Cote S, Zhang AC, Ahmadzai V, et al. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction. Cochrane Database Syst Rev. 2020; 3: CD013559.

  • 42

    Sindt CW, Foulks GN. Efficacy of an artificial tear emulsion in patients with dry eye associated with meibomian gland dysfunction. Clin Ophthalmol. 2013; 7: 1713–1722.

  • 43

    Dausch D, Lee S, Dausch S, et al. Comparative study of treatment of the dry eye syndrome due to disturbances of the tear film lipid layer with lipid-containing tear substitutes. [Vergleichende Studie zur Therapie des trockenen Auges bedingt durch Lipidphasenstörungen mit lipidhaltigen Tränenpräparaten.] Klin Monbl Augenheilkd. 2006; 223: 974–983. [German]

  • 44

    Wladis EJ, Bradley EA, Bilyk JR, et al. Oral antibiotics for meibomian gland-related ocular surface disease: a report by the American Academy of Ophthalmology. Ophthalmology 2016; 123: 492–496.

  • 45

    Akyol-Salman I, Azizi S, Mumcu U, et al. Efficacy of topical N-acetylcysteine in the treatment of meibomian gland dysfunction. J Ocul Pharmacol Ther. 2010; 26: 329–333.

  • 46

    Liu A, Ji J. Omega-3 essential fatty acids therapy for dry eye syndrome: a meta-analysis of randomized controlled studies. Med Sci Monit. 2014; 20: 1583–1589.

  • 47

    Calder PC. Polyunsaturated fatty acids, inflammation, and immunity. Lipids 2001; 36: 1007–1024.

  • 48

    Lee H, Chung B, Kim KS, et al. Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial. Am J Ophthalmol. 2014; 158: 1172–1183.e1.

  • 49

    Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006; 25: 171–175.

  • 50

    Sullivan DA, Sullivan BD, Ullman MD, et al. Androgen influence on the meibomian gland. Invest Ophthalmol Vis Sci. 2000; 41: 3732–3742.

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Oct 2020 0 0 0
Nov 2020 0 0 0
Dec 2020 0 0 0
Jan 2021 0 129 164
Feb 2021 0 84 124
Mar 2021 0 142 151
Apr 2021 0 17 56